DEPARTMENT OF RADIO DIAGNOSIS

UHID / IP NO	40007315 (14047)	RISNo./Status:	4014487/
Patient Name :	Mr. RAKESH SHARMA	Age/Gender:	31 Y/M
Referred By :	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	Ward/Bed No:	OPD
Bill Date/No :	06/11/2023 11:06AM/ OPSCR23- 24/7421	Scan Date :	
Report Date :	06/11/2023 12:01PM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

USG REPORT - ABDOMEN AND PELVIS

LIVER:

Is normal in size and uniform echo texture.

No obvious focal lesion seen. No intra hepatic biliary radical dilatation seen.

GALL BLADDER:

Partially distended.

PANCREAS:

Is obscured by bowel gases.

SPLEEN:

Appears normal in size and it shows uniform echo texture.

RIGHT KIDNEY:

The shape, size and contour of the right kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

LEFT KIDNEY:

The shape, size and contour of the left kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

URINARY BLADDER:

Partially distended.

PROSTATE:

Is normal in size, measuring approx. 20cc in volume.

No focal fluid collections seen.

IMPRESSION:

No significant sonographic abnormality detected.

DR. RENU JADIYA

Row Jadys

Consultant - Radiology

MBBS, DNB

DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40007315 (14047)	RISNo./Status:	4014487/
Patient Name:	Mr. RAKESH SHARMA	Age/Gender:	31 Y/M
Referred By :	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	Ward/Bed No:	OPD
Bill Date/No:	06/11/2023 11:06AM/ OPSCR23- 24/7421	Scan Date :	
Report Date:	06/11/2023 11:42AM	Company Name:	Final

REFERRAL REASON: - HEALTH CHECKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

Normal Normal								
IVSD	9.0	6-12mm			LVIDS	25.4	20-40mm	
LVIDD	39.4		32-	57mm		LVPWS	15.9	mm
LVPWD	9.0		6-1	2mm		AO	32.2	19-37mm
IVSS	15.4		J	nm		LA	27.2	19-40mm
LVEF	64-66		>:	55%		RA	-	mm
	<u>DOPPLEI</u>	R MEA	SUREM	1ENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY	VELOCITY (m/s)					REGURGITATION	
					(mm	Hg <u>)</u>		
MITRAL	NORMAL	\mathbf{E}	0.93	e'		-		NIL
VALVE		A	0.39	E/e'				
TRICUSPID	NORMAL		E 0.59		-		NIL	
VALVE		A 0.47						
AORTIC	NORMAL	1.16		-		NIL		
VALVE								
PULMONARY VALVE	NORMAL	0.62		0.62			NIL	

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 64-66%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

Patient Name Mr. RAKESH SHARMA

 UHID
 326819

 Age/Gender
 31 Yrs/Male

 IP/OP Location
 O-OPD

Referred By Dr. EHCC Consultant

Mobile No. 9773349797

Lab No 563831

 Collection Date
 06/11/2023 12:32PM

 Receiving Date
 06/11/2023 12:34PM

Report Date 06/11/2023 1:26PM

Report Status Final



BIOCHEMISTRY

Test Name	Result	Unit	Biological Ref. Range
			Sample: WHOLE BLOOD EDTA
HBA1C	5.6	%	< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes
			Known Diabetic Patients < 7 % Excellent Control 7 - 8 % Good Control > 8 % Poor Control

Method: - High - performance liquid chromatography HPLC Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

End Of Report

RESULT ENTERED BY : Mr. MAHENDRA KUMAR

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS|MD| PATHOLOGY Dr. ASHISH SHARMA
CONSULTANT & INCHARGE PATHOLOGY
MBBS|MD| PATHOLOGY

Page: 1 Of 1

Patient Name Mr. RAKESH SHARMA Lab No 4014487 UHID 40007315 **Collection Date** 06/11/2023 11:18AM 06/11/2023 11:30AM Age/Gender 31 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

Mobile No. 8107945949

BIOCHEMISTRY

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 98.2
 mg/dl
 74 - 106

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) 103.2 mg/dl Non – Diabetic: - < 140 mg/dl

Pre – Diabetic: - 140-199 mg/dl Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

THYROID T3 T4 TSH Sample: Serum

Т3	1.310	ng/mL	0.970 - 1.690
Т4	7.96	ug/dl	5.53 - 11.00
TSH	3.32	μIU/mL	0.40 - 4.05

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

Patient Name	Mr. RAKESH SHARMA	Lab No	4014487
UHID	40007315	Collection Date	06/11/2023 11:18AM
Age/Gender	31 Yrs/Male	Receiving Date	06/11/2023 11:30AM
IP/OP Location	O-OPD	Report Date	06/11/2023 3:41PM
Referred By	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	Report Status	Final
Mobile No.	8107945949		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.45	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.32	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.13	mg/dl	0.00 - 0.40	
SGOT	30.6	U/L	0.0 - 40.0	
SGPT	30.0	U/L	0.0 - 40.0	
TOTAL PROTEIN	7.6	g/dl	6.6 - 8.7	
ALBUMIN	5.2	g/dl	3.5 - 5.2	
GLOBULIN	2.4		1.8 - 3.6	
ALKALINE PHOSPHATASE	79.1	U/L	53 - 128	
A/G RATIO	2.2	Ratio	1.5 - 2.5	
GGTP	13.9	U/L	10.0 - 55.0	

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

Patient Name Mr. RAKESH SHARMA Lab No 4014487

 UHID
 40007315
 Collection Date
 06/11/2023 11:18AM

 Age/Gender
 31 Yrs/Male
 Receiving Date
 06/11/2023 11:30AM

 IP/OP Location
 O-OPD
 Report Date
 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

Mobile No. 8107945949

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Bivret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

TOTAL CHOLESTEROL	189		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	39.7		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	128.3		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	27	mg/dl	10 - 50
TRIGLYCERIDES	137.4		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	4.8	%	

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

Patient Name Mr. RAKESH SHARMA Lab No 4014487

UHID 40007315 **Collection Date** 06/11/2023 11:18AM 06/11/2023 11:30AM Age/Gender **Receiving Date** 31 Yrs/Male **Report Date IP/OP Location** O-OPD 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final

Mobile No. 8107945949

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	26.60	mg/dl	16.60 - 48.50
BUN	12.4	mg/dl	6 - 20
CREATININE	0.85	mg/dl	0.60 - 1.10
SODIUM	138.9	mmol/L	136 - 145
POTASSIUM	3.88	mmol/L	3.50 - 5.50
CHLORIDE	103.6	mmol/L	98 - 107
URIC ACID	3.4 L	mg/dl	3.5 - 7.2
CALCIUM	9.97	mg/dl	8.60 - 10.30

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

 Patient Name
 Mr. RAKESH SHARMA
 Lab No
 4014487

 UHID
 40007315
 Collection Date
 06/11/2023 11:18AM

 Age/Gender
 31 Yrs/Male
 Receiving Date
 06/11/2023 11:30AM

 IP/OP Location
 O-OPD
 Report Date
 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

Mobile No. 8107945949

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the

kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption.

POTASSIUM: - Method: ISE electrode. Intrpretation: -Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure. High level: Debudration shock severe burns DKA renal failure.

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: - Method: ISE electrode. Interpretation: -Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

RESULT ENTERED BY : NEETU SHARMA

Patient Name Mr. RAKESH SHARMA Lab No 4014487 UHID 40007315 **Collection Date** 06/11/2023 11:18AM 06/11/2023 11:30AM Age/Gender **Receiving Date** 31 Yrs/Male **Report Date IP/OP Location** O-OPD 06/11/2023 3:41PM

Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Referred By Report Status** Final

Mobile No. 8107945949

BLOOD BANK INVESTIGATION

Biological Ref. Range Test Name Result Unit

BLOOD GROUPING "B" Rh Positive

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

Patient Name Lab No Mr. RAKESH SHARMA 4014487 **Collection Date** 06/11/2023 11:18AM UHID 40007315 06/11/2023 11:30AM Age/Gender **Receiving Date** 31 Yrs/Male **Report Date** O-OPD **IP/OP Location** 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

Mobile No. 8107945949

CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				·
VOLUME	30	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	5.0 L		5.5 - 7.0	
SPECIFIC GRAVITY	1.020		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	+			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	2-3	/hpf	0 - 3	
RBCS/HPF	10-12	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	2-4	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

Patient Name Mr. RAKESH SHARMA Lab No 4014487 UHID 40007315 **Collection Date** 06/11/2023 11:18AM 06/11/2023 11:30AM Age/Gender 31 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final

8107945949 Mobile No.

CLINICAL PATHOLOGY

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

Patient Name Mr. RAKESH SHARMA Lab No 4014487 UHID 40007315 **Collection Date** 06/11/2023 11:18AM 06/11/2023 11:30AM Age/Gender 31 Yrs/Male **Receiving Date** Report Date **IP/OP Location** O-OPD 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final

Mobile No. 8107945949

HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Range
CBC (COMPLETE BLOOD COUNT)			Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	13.4	g/dl	13.0 - 17.0
PACKED CELL VOLUME(PCV)	42.4	%	40.0 - 50.0
MCV	88.9	fl	82 - 92
MCH	28.1	pg	27 - 32
MCHC	31.6 L	g/dl	32 - 36
RBC COUNT	4.77	millions/cu.mm	4.50 - 5.50
TLC (TOTAL WBC COUNT)	5.80	10^3/ uL	4 - 10
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHILS	45.7	%	40 - 80
LYMPHOCYTE	37.2	%	20 - 40
EOSINOPHILS	7.6 H	%	1 - 6
MONOCYTES	8.6	%	2 - 10
BASOPHIL	0.9 L	%	1 - 2
PLATELET COUNT	2.19	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation bysysmex. MCH: - Method: - Calculation bysysmex.
MCHC: - Method: - Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry $\textbf{LYMPHOCYTS} : - \ \texttt{Method:} \ \texttt{Optical} \ \texttt{detectorblock} \ \texttt{based} \ \texttt{on} \ \texttt{Flowcytometry}$ EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 05 mm/1st hr 0 - 15

RESULT ENTERED BY: NEETU SHARMA

Dr. ABHINAY VERMA

Patient Name Lab No Mr. RAKESH SHARMA 4014487 UHID 40007315 **Collection Date** 06/11/2023 11:18AM 06/11/2023 11:30AM Age/Gender **Receiving Date** 31 Yrs/Male **Report Date** O-OPD **IP/OP Location** 06/11/2023 3:41PM **Referred By** Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final Mobile No. 8107945949

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : NEETU SHARMA

Page: 10 Of 11

Patient Name Mr. RAKESH SHARMA Lab No 4014487 UHID 40007315 **Collection Date** 06/11/2023 11:18AM 06/11/2023 11:30AM Age/Gender **Receiving Date** 31 Yrs/Male **Report Date IP/OP Location** O-OPD 06/11/2023 3:41PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

Mobile No. 8107945949

X Ray

Test Name Result Unit Biological Ref. Range

X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape andoutlines.

Cardiac shadow is within normal limits.

Visualized bony thorax is unremarkable.

Correlate clinically& with other related investigations.

End Of Report

RESULT ENTERED BY : NEETU SHARMA

The state of the s

APOORVA JETWANI

Select